Brief: Hansa Biopharma AB Announces Publication Of Important Data From An Investigator-Initiated Study In Anti-GBM In Nephrology Journal JASN

Hansa Biopharma AB

08/03/2022 22:47

March 8 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * ANNOUNCES PUBLICATION OF IMPORTANT DATA FROM AN
INVESTIGATOR-INITIATED STUDY IN ANTI-GBM IN NEPHROLOGY JOURNAL
JASN
    * RESULTS SHOW KIDNEY FUNCTION AT 6 MONTHS WAS SIGNIFICANTLY
BETTER THAN IN PREVIOUSLY PUBLISHED COHORTS, WITHOUT SAFETY
CONCERNS
    * HANSA BIOPHARMA- RESULTS HIGHLIGHT POTENTIAL OF IMLIFIDASE
BEYOND KIDNEY TRANSPLANTATION, PAVING WAY FOR  PHASE 3 STUDY IN
ANTI-GBM, PLANNED TO BEGIN THIS YEAR
    * IMLIFIDASE RAPIDLY AND COMPLETELY REDUCED PATHOGENIC
ANTI-GBM
ANTIBODY LEVELS TO BELOW REFERENCE RANGE.
    * AT SIX MONTHS 67% OF INCLUDED PATIENTS HAD FUNCTIONING
KIDNEYS
VERSUS 18% IN A HISTORICAL CONTROL COHORT
    * PUBLICATION RECOGNISES STUDY'S SIGNIFICANCE IN AUTOIMMUNE
DISEASES

Source text for Eikon:  ID:nWkrSqvMX 
Further company coverage:  HNSA.ST 

 ((Reuters.Briefs@thomsonreuters.com;))